Zelluna ASA (OSL:ZLNA)
Norway · Delayed Price · Currency is NOK | Market Cap | 467.32M +135.5% |
| Revenue (ttm) | n/a +628.3% |
| Net Income | -104.59M |
| EPS | -3.92 |
| Shares Out | 29.86M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 17,850 |
| Open | 16.10 |
| Previous Close | 16.10 |
| Day's Range | 15.30 - 16.10 |
| 52-Week Range | 8.20 - 35.80 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Nov 5, 2026 |
About Zelluna ASA
Zelluna ASA, a clinical-stage biotechnology company, engages in the development of T-cell receptor guided natural killer cell therapies in Norway. It develops ZI-MA4-1 which is in Phase I clinical trial for the treatment of non-small cell lung cancer, ovarian, and head and neck synovial sarcoma; ZI-KL1-1 which is in preclinical trial for the treatment of breast, gastric, lung, pancreatic, and cervix cancers; and ZI-PR-1 which is in discovery stage for the treatment of solid tumors. The company was incorporated in 2016 and is headquartered in Os... [Read more]
Financial Performance
Financial StatementsNews
Zelluna ASA Earnings Call Transcript: Q3 2026
Two patients received dose-level-1 treatment with no dose-limiting toxicities, while imaging and efficacy assessments remain ongoing. Cash was NOK 60m at Q3-end, and cohort 2 is expected by early Q2 2027.
Zelluna ASA Slides: Q3 2026
Zelluna ASA has posted slides in relation to its Q3 2026 quarterly earnings report, which was published on November 5, 2026.
Zelluna ASA Quarterly report: Q3 2026
Zelluna ASA has published its Q3 2026 quarterly earnings report on November 5, 2026.
Zelluna ASA Transcript: BioStock Life Science Summit 2026
ZI-MA4-1, a MAGE-A4-targeting TCR-NK therapy, has entered dose escalation across four solid-tumor indications. The platform combines dual cancer recognition with scalable manufacturing, while early patient data could shape registration and strategic options.
Zelluna Reports Q2 2026 Results, Advances First-in-Human TCR-NK Trial
(RTTNews) - Zelluna ASA (ZLNA), a clinical-stage company developing allogeneic "off-the-shelf" T Cell Receptor-based Natural Killer (TCR-NK) cell therapies for solid cancers, reported second-quarter 2...
Zelluna ASA Earnings Call Transcript: Q2 2026
Key Q2 2026 milestones achieved, including first patient dosed and favorable initial safety data for the lead program. Financial position strengthened with new capital and grant funding, extending runway into Q3 2027. Further clinical data and potential strategic options expected as the study progresses.
Zelluna ASA Quarterly report: Q2 2026
Zelluna ASA has published its Q2 2026 quarterly earnings report on August 20, 2026.
Zelluna ASA Slides: Q2 2026
Zelluna ASA has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on August 20, 2026.
Zelluna Advances Phase 1 ZIMA-101 Trial Following Positive Safety Review From Independent Committee
(RTTNews) - Zelluna ASA (ZLNA) a clinical-stage company, said that the Independent Data Monitoring Committee (IDMC) has recommended continuing patient enrollment in the Phase 1 ZIMA-101 trial followin...
Zelluna ASA Earnings Call Transcript: Q1 2026
First clinical site activated for TCR-NK cell therapy trial in solid tumors, with initial human data expected mid-2026. Cash position of NOK 50 million supports runway into Q1 2027, and pipeline expansion continues with AI-driven programs.
Zelluna ASA Quarterly report: Q1 2026
Zelluna ASA has published its Q1 2026 quarterly earnings report on May 7, 2026.
Zelluna ASA Slides: Q1 2026
Zelluna ASA has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on May 7, 2026.
Zelluna ASA Transcript: Capital Markets Update 2026
A novel off-the-shelf cell therapy platform is advancing to clinical trials for solid tumors, targeting MAGE-A4 with a dual TCR-NK mechanism. The phase I study will focus on safety and proof of mechanism, with initial data expected from mid-2026.
Zelluna ASA Slides: FY 2026
Zelluna ASA has posted slides in relation to its FY 2026 quarterly earnings report, which was published on April 14, 2026.
Zelluna ASA Earnings Call Transcript: Q4 2025
Raised NOK 58 million, extending cash runway into Q1 2027, and advanced ZIMA-401 toward first-in-human trials with CTA approval expected in H1 2026. Preclinical data showed strong efficacy, and the company is focusing on scalable, off-the-shelf cell therapies for solid tumors.
Zelluna ASA Annual report: Q4 2025
Zelluna ASA has published its Q4 2025 annual report on February 12, 2026.
Zelluna ASA Quarterly report: Q4 2025
Zelluna ASA has published its Q4 2025 quarterly earnings report on February 12, 2026.
Zelluna ASA Slides: Q4 2025
Zelluna ASA has posted slides in relation to its Q4 2025 quarterly earnings report, which was published on February 12, 2026.